



01-28-04

Docket 17656 CON (OCU)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: VERNON G. WONG et al.)	Examiner:
)	
Serial Number: 10/671,816)	
)	Art Unit: 1615
Filed: September 25, 2003)	
)	Confirmation No: 6866
For: METHODS FOR TREATING)	
INFLAMMATION-MEDIATED)	
<u>CONDITIONS OF THE EYE</u>)	Irvine, California

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Applicant's provide with regard to the patent application entitled METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE, filed herewith one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: April 26, 2004



Stephen Donovan
Registration Number 33,433

Please direct all inquiries and correspondence to:


Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: 714.246.4026
Fax: 714.246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date April 26, 2004, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV193718911US addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Bartholomew
Name of person mailing paper

Signature of person mailing paper

Date: April 26, 2004



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17656 CON (OCU)	SERIAL NO.: 10/671,816
APPLICANT: VERNON G. WONG et al.	TITLE: METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE
FILING DATE: September 23, 2003	GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (If applicable)
	AA	4,997,652	3/5/1991	Wong, Vernon G.			
	AB	5,164,188	11/17/1992	Wong, Vernon G.			
	AC	5,443,505	8/22/1995	Wong, Vernon G.			
	AD	5,501,856	3/26/1996	Ohtori et al.			
	AE	5,766,242	6/16/1998	Wong, Vernon G.			
	AF	5,824,072	10/20/1998	Wong, Vernon G.			
	AG	5,869,079	2/9/1999	Wong, Vernon G.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	American Academy of Ophthalmology; Basic and Clinical Science Course: Intraocular inflammation and Uveitis Section 9, 2003-2004 57-80, 102-103, 152-156
	CB	Apel et al.; A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy; Current Eye Research; 1995; 659-667
	CC	Bloch-Michel, Etienne; Opening Address: Intermediate Uveitis; Boke WRF, Manthey KF, Nussenblatt RB (eds): Intermediate Uveitis; Dev Ophthalmol; Basel, Karger; 1992, Vol 23; 1-2
	CD	Bodor et al.; A comparison of intraocular pressure elevation activity of loteprednol etabonate and dexamethasone in rabbits; Current Eye Research, 1992, 11, 525-30
	CE	Boke WRF, Manthey KF, Nussenblatt RB (eds): Clinical Picture of Intermediate Uveitis; Intermediate Uveitis; Dev Ophthalmol; Basel, Karger; 1992, Vol 23; 20-27
	CF	Cheng et al.; Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis; Investigative Ophthalmology & Visual Science; 2/1995, Vol. 36, No. 2; 442-453

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17656 CON (OCU)	SERIAL NO.: 10/671,816
APPLICANT: VERNON G. WONG et al.	TITLE: METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE
FILING DATE: September 23, 2003	GROUP: 1615

	CG	De Jong et al.; <i>New insights into the hydrolytic degradation of poly (lactic acid): participation of the alcohol terminum</i> ; <u>Polymer</u> 42 (2001) 2795-2802
	CH	Gould et al.; <i>Fifty:fifty poly (DL glycolic acid-lactic acid) copolymer as a drug delivery system for 5-fluorouracil: a histopathological evaluation</i> ; <u>Can J Ophthalmol</u> , Vol. 29, No. 4, 1994; 168-171
	CI	Hayes, Robert C. Jr., <i>Adrenocorticotrophic Hormone: Adrenocortical Steroids and their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones</i> , Chapter 60 at pg 1447 of <u>Goodman and Gilman's: The pharmacological Basis of Therapeutics</u> , Eighth Edition, Pergamon Press 1990
	CJ	Kwak et al.; <i>Evaluation of the Retinal Toxicity and Pharmacokinetics of Dexamethasone After Intravitreal Injection</i> ; <u>Arch Ophthalmol</u> , Vol. 110, 2/1992, 259-266
	CK	Lee et al.; <i>Drug delivery to the posterior segment</i> ; Chapter 25 of <u>Principles of vitreoretinal therapy</u> , Vol. 1, Part 1, 1989, 483-498
	CL	Maurice, David M.; <i>Micropharmaceutics of the Eye</i> ; <u>Ocular Inflammation Ther.</u> , 1; 1983, 97-102
	CM	Ogden et al. editors; <i>Retina - Basic Science and Inherited Retinal Disease</i> Vol. 1, St. Louis; CV Mosby
	CN	Olsen et al.; <i>Human Scleral Permeability - Effects of Age, Cryotherapy, Transscleral Diode Laser, and Surgical Thinning</i> ; <u>Investigative Ophthalmology & Visual Science</u> ; 8/1995, Vol. 36, No. 9, 1893-1903
	CO	Park et al.; <i>A new preparation method for protein loaded poly (D,L-lactic-coglycolic acid) Microspheres and protein release mechanism study</i> ; <u>Journal of Controlled Release</u> ; 55 (1998), 181-191
	CP	Renfro et al.; <i>Ocular Effects of Topical and Systemic Steroids</i> ; <u>Dermatologic Clinics</u> , Vol. 10, No. 3, 7/1992, 505-512
	CQ	Tracy et al.; <i>Factors affecting the degradation rate of poly (lactide-co-glycolide) Microspheres in vivo and in vitro</i> ; <u>Biomaterials</u> ; 20 (1999), 1057-1062
	CR	Schwartz, Bernard; <i>The Response of Ocular Pressure to Corticosteroids</i> ; <u>Ophthalmol. Clin. North Am.</u> , 6; 929-89

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17656 CON (OCU)	SERIAL NO.: 10/671,816
APPLICANT: VERNON G. WONG et al.	TITLE: METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE
FILING DATE: September 23, 2003	GROUP: 1615

	CS	Skalka et al.; <i>Effect of Corticosteroids on Cataract Formation</i> ; <u>Arch Ophthalmol</u> ; Vol. 98, 10/1980, 1773-1777
	CT	Tracy et al.; <i>Factors affecting the degradation rate of poly (lactide-co-glycolide) Microspheres in vivo and in vitro</i> ; <u>Biomaterials</u> ; 20 (1999), 1057-1062
	CU	United States Pharmacopeia: The National Formulary 18; 1995, 1790-1798
	CV	Zhou et al.; <i>Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy</i> ; <u>Journal of Controlled Release</u> ; 55, 281-295
	CW	
	CX	
	CY	
	CZ	

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.